EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE
Pre-LaunchNDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE by Cipla is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ].
Drug data last refreshed 19h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate—three antiretroviral agents with complementary mechanisms against HIV-1. The combination leverages synergistic antiviral activity to suppress viral replication across multiple targets. It is administered orally as a single tablet, simplifying treatment adherence in HIV management.
PRE_LAUNCH
Pre-launch positioning offers significant growth potential as the product enters a mature but sustained HIV market; team size and investment will depend on Cipla's global distribution strategy.
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch product offers exposure to HIV market dynamics and global health strategies in emerging markets where generic cost leadership is paramount. Career growth depends on successful market penetration and differentiation against established competitors; roles will emphasize access, pricing, and provider education over innovation-driven medical affairs.
Brand ManagerMarket Access Manager
Worked on EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.